Alpha-1 Antitrypsin Deficiency Treatment Market size in terms of volume and value 2020-2027

 Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 2,914.7 Million by 2025 at a CAGR of 10.50%.

Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8319 

Market Synopsis

Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the global alpha-1 antitrypsin deficiency treatment market trends.

Strategic mergers & acquisitions are also projected to boost market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images. For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.

High unmet medical needs in developing economies are directly providing lucrative opportunities for the market growth.

Segmentation

By Drugs:

• Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.
• Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.
• Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.
• Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.

By Route of Administration:

• Oral: The segment is expected to hold the largest market share.
• Intravenous: The segment is expected to grow at the fastest CAGR.
• Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.
• Others: Subcutaneous and intramuscular routes of administration.

By Distribution Channel:

• Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.
• Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.
• Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.

By Region

• Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

• Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

• Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.

• Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

• Kamada Pharmaceuticals (Israel)
• CSL Behring LLC (US)
• Grifols, S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• GlaxoSmithKline plc (UK)
• Boehringer Ingelheim GmbH (Germany)
• AstraZeneca (UK)
• Vectura Group plc (UK)
• Pfizer Inc. (US)
• Mylan Inc. (US)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319